Hypersensitivity from intravenous iron products

Immunology and Allergy Clinics of North America

Volumn 34, Issue 3, 2014, Pages 707-723

  Bircher, Andreas J ^a   Auerbach, Michael ^b,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Auerbach Hematology and Oncology   (United States)

Author keywords

Adverse drug reaction; Hypersensitivity; Intravenous iron; Toxicity

Indexed keywords

DIPHENHYDRAMINE; FERPLEX 40; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERROUS GLUCONATE; FERUMOXYTOL; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IRON DERIVATIVE; IRON DEXTRAN; IRON ISOMALTOSE; IRON PROTEIN SUCCINYLATE; IRON SACCHARATE; MONOFER; TRANSFERRIN; UNCLASSIFIED DRUG; FERRIC ION; FERROUS ION; IRON;

ALLERGIC REACTION; ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTHRITIS; BACKACHE; BRADYCARDIA; BRONCHOSPASM; BURNING SENSATION; COLIC; COUGHING; DELAYED HYPERSENSITIVITY; DIAPHORESIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; EPIGASTRIC PAIN; FAINTNESS; FEVER; FLUSHING; HEADACHE; HEART PALPITATION; HEMODIALYSIS; HUMAN; HYPERESTHESIA; HYPERTENSION; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; INFECTION; INJECTION SITE PAIN; INJECTION SITE PIGMENTATION; INJECTION SITE REACTION; INTRACUTANEOUS TEST; IRON DEFICIENCY; LOW BACK PAIN; LYMPHADENOPATHY; MEDICAL HISTORY; METALLIC TASTE; MYALGIA; NAUSEA; PATCH TEST; PATHOPHYSIOLOGY; PREMEDICATION; PRICK TEST; PRIORITY JOURNAL; PROVOCATION TEST; PRURITUS; RASH; REVIEW; SHOCK; SKIN DISEASE; SOMNOLENCE; STRIDOR; TACHYCARDIA; TACHYPNEA; THORAX PAIN; TONGUE BURNING; TONGUE DISEASE; TONGUE EDEMA; TONGUE SWELLING; UNCONSCIOUSNESS; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING; HYPERSENSITIVITY, DELAYED; HYPERSENSITIVITY, IMMEDIATE; INTRAVENOUS DRUG ADMINISTRATION; RISK FACTOR;

ADMINISTRATION, INTRAVENOUS; DRUG HYPERSENSITIVITY; FERRIC COMPOUNDS; FERROUS COMPOUNDS; HUMANS; HYPERSENSITIVITY, DELAYED; HYPERSENSITIVITY, IMMEDIATE; IRON; RISK FACTORS;

EID: 84904068210     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2014.04.013     Document Type: Review

References (86)

1. Auerbach M., Ballard H., Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 2007, 369(9572):1502-1504.
2. Palmiere C., Comment L., Mangin P. Allergic reactions following contrast material administration: nomenclature, classification, and mechanisms. Int J Legal Med 2014, 128(1):95-103.
3. Farnam K., Chang C., Teuber S., et al. Nonallergic drug hypersensitivity reactions. Int Arch Allergy Immunol 2012, 159(4):327-345.
4. Johansson S.G.O., Bieber T., Dahl R., et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. JAllergy Clin Immunol 2004, 113(5):832-836.
5. Sampson H., Muñoz Furlong A., Campbell R., et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. JAllergy Clin Immunol 2006, 117(2):391-397.
6. Gamerdinger K., Moulon C., Karp D.R., et al. Anew type of metal recognition by human T cells: contact residues for peptide-independent bridging of T cell receptor and major histocompatibility complex by nickel. JExp Med 2003, 197(10):1345-1353.
7. Schmidt M., Raghavan B., Müller V., et al. Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat Immunol 2010, 11(9):814-819.
8. Lansdown A.B. Physiological and toxicological changes in the skin resulting from the action and interaction of metal ions. Crit Rev Toxicol 1995, 25(5):397-462.
9. Raghavan B., Martin S., Esser P., et al. Metal allergens nickel and cobalt facilitate TLR4 homodimerization independently of MD2. EMBO Rep 2012, 13(12):1109-1115.
10. Bircher A.J., Hédin H., Berglund A. Probable grade IV dextran-induced anaphylactic reaction despite hapten inhibition. JAllergy Clin Immunol 1995, 95(2):633-634.
11. Bailie G., Clark J., Lane C., et al. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005, 20(7):1443-1449.
12. Ring J., Behrendt H., de Weck A. History and classification of anaphylaxis. Anaphylaxis chem immunol allergy 2010, vol. 95:1-11. Karger, Basel (Switzerland).
13. Bircher A.J., Izakovic J., Bigliardi P.L. Oral tolerance of carboxymethylcellulose in patients with anaphylaxis to parenteral carboxymethylcellulose. Ann Allergy Asthma Immunol 2004, 92(5):580-581.
14. Bigliardi P.L., Izakovic J., Weber J.M., et al. Anaphylaxis to the carbohydrate carboxymethylcellulose in parenteral corticosteroid preparations. Dermatology 2003, 207(1):100-103.
15. Wolver S., Sun D., Commins S., et al. Apeculiar cause of anaphylaxis: no more steak? The journey to discovery of a newly recognized allergy to galactose-alpha-1,3-galactose found in mammalian meat. JGen Intern Med 2013, 28(2):322-325.
16. Potthoff S.A., Münch H.G. Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease. Dtsch Med Wochenschr 2013, 138(24):1312-1317. [in German].
17. Danielson B.G. Structure, chemistry, and pharmacokinetics of intravenous iron agents. JAm Soc Nephrol 2004, 15(Suppl 2):S93-S98.
18. Pichler W.J. Immune mechanism of drug hypersensitivity. Immunol Allergy Clin North Am 2004, 24(3):373-397.
19. Novey H.S., Pahl M., Haydik I., et al. Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy 1994, 72(3):224-228.
20. Hoigné R., Breymann C., Künzi U.P., et al. Parenteral iron therapy: problems andpossible solutions. Schweiz Med Wochenschr 1998, 128(14):528-535. [inGerman].
21. Zinderman C., Landow L., Wise R. Anaphylactoid reactions to dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004. JVasc Surg 2006, 43(5):1004-1009.
22. Kraft D., Hedin H., Richter W., et al. Immunoglobulin class and subclass distribution of dextran-reactive antibodies in human reactors and non reactors to clinical dextran. Allergy 1982, 37(7):481-489.
23. Healy D.P., Sahai J.V., Fuller S.H., et al. Vancomycin-induced histamine release and "red man syndrome": comparison of 1- and 2-hour infusions. Antimicrob Agents Chemother 1990, 34(4):550-554.
24. Scherer K., Spoerl D., Bircher A.J. Adverse drug reactions to biologics. JDtsch Dermatol Ges 2010, 8(6):411-426.
25. Vogel W. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs 2010, 14(2):E10-E21.
26. Levy J.H., Marty A.T. Vancomycin and adverse drug reactions. Crit Care Med 1993, 21(8):1107-1108.
27. Auerbach M., Coyne D., Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol 2008, 83(7):580-588.
28. Nissim J.A. Intravenous administration of iron. Lancet 1947, 2(6463):49-51.
29. Marchasin S., Wallerstein R.O. The treatment of iron-deficiency anemia with intravenous iron dextran. Blood 1964, 23(3):354-358.
30. Baird I.M., Podmore D.A. Intramuscular iron therapy in iron-deficiency anaemia. Lancet 1954, 267(6845):942-946.
31. Hamstra R.D., Block M.H., Schocket A.L. Intravenous iron dextran in clinical medicine. JAMA 1980, 243(17):1726-1731.
32. Eschbach J.W., Kelly M.R., Haley N.R., et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. NEngl J Med 1989, 321(3):158-163.
33. Fishbane S., Frei G.L., Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995, 26(1):41-46.
34. Faich G., Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999, 33(3):464-470.
35. Coyne D., Adkinson N.F., Nissenson A., et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 2003, 63(1):217-224.
36. Michael B., Coyne D., Fishbane S., et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002, 61(5):1830-1839.
37. Chertow G., Mason P., Vaage Nilsen O., et al. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004, 19(6):1571-1575.
38. Rodgers G., Auerbach M., Cella D., et al. High-molecular weight iron dextran: a wolf in sheep's clothing?. JAm Soc Nephrol 2008, 19(5):833-834.
39. Fishbane S., Ungureanu V.D., Maesaka J.K., et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996, 28(4):529-534.
40. Barton J.C., Barton E.H., Bertoli L.F., et al. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med 2000, 109(1):27-32.
41. Okam M., Mandell E., Hevelone N., et al. Comparative rates of adverse events with different formulations of intravenous iron. Am J Hematol 2012, 87(11):E123-E124.
42. Sav T., Tokgoz B., Sipahioglu M., et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?. Ren Fail 2007, 29(4):423-426.
43. Moniem K.A., Bhandari S. Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations. Transfus Altern Transfus Med 2007, 9(1):37-42.
44. Critchley J., Dundar Y. Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and iron sucrose): a systematic review. Transfus Alternat Transfus Med 2007, 9(1):8-36.
45. Macdougll I.C., Strauss W.E., McLaughlin J., et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol 2014, 9(4):705-712.
46. Auerbach M., Al Talib K. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int 2008, 73(5):528-530.
47. Coyne D. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int 2011, 80(3):240-244.
48. Rosner M., Auerbach M. Ferumoxytol for the treatment of iron deficiency. Expert Rev Hematol 2011, 4(4):399-406.
49. Nemeth E., Tuttle M., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306(5704):2090-2093.
50. Nemeth E., Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009, 122(2-3):78-86.
51. Jahn M., Andreasen H., Fütterer S., et al. Acomparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011, 78(3):480-491.
52. Wysowski D., Swartz L., Borders Hemphill B.V., et al. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol 2010, 85(9):650-654.
53. Onken J.E., Bregman D.B., Harrington R.A., et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant 2014, 29(4):833-842.
54. Auerbach M., Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program 2010, 2010(1):338-347.
55. Auerbach M., Chaudhry M., Goldman H., et al. Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. JLab Clin Med 1998, 131(3):257-260.
56. Kalantar-Zadeh K., Regidor D.L., McAllister C.J., et al. Time-dependent associations between iron and mortality in hemodialysis patients. JAm Soc Nephrol 2005, 16(10):3070-3080.
57. Feldman H., Joffe M., Robinson B., et al. Administration of parenteral iron and mortality among hemodialysis patients. JAm Soc Nephrol 2004, 15(6):1623-1632.
58. Saadeh C., Srkalovic G. Acute hypersensitivity reaction to ferric gluconate in a premedicated patient. Ann Pharmacother 2005, 39(12):2124-2127.
59. Cuciti C., Mayer D.C., Arnette R., et al. Anaphylactoid reaction to intravenous sodium ferric gluconate complex during pregnancy. Int J Obstet Anesth 2005, 14(4):362-364.
60. Sirvent-Pedreño A., Enríquez-Ascarza R., Redondo-Pachón M.D., et al. Adverse reaction to intravenous iron: hypersensitivity or secondary side effect?. Nefrología 2013, 33(1):148-149.
61. Larramendi C., Marco F., García-Abujeta J., et al. Acute allergic reaction to an iron compound in a milk-allergic patient. Pediatr Allergy Immunol 2006, 17(3):230-233.
62. Nater J.P. Epidermale Überempfindlichkeit gegen Eisen. Hautarzt 1960, 11:223-224.
63. Baer R.L. Allergic contact sensitization to iron. JAllergy Clin Immunol 1973, 51(7):35-38.
64. Scheiber Mojdehkar B., Lutzky B., Schaufler R., et al. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation. JAm Soc Nephrol 2004, 15(6):1648-1655.
65. Brewster U., Perazella M. Intravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial 2004, 17(1):57-60.
66. Bullen J., Rogers H., Spalding P., et al. Iron and infection: the heart of the matter. FEMS Immunol Med Microbiol 2005, 43(3):325-330.
67. Hoen B., Paul Dauphin A., Kessler M. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 2002, 57(6):457-461.
68. Brookhart M.A., Freburger J., Ellis A., et al. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. JAm Soc Nephrol 2013, 24(7):1151-1158.
69. Steinmetz T., Tschechne B., Harlin O., et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 2013, 24(2):475-482.
70. Beguin Y., Maertens J., De Prijck B., et al. Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. Am J Hematol 2013, 88(12):990-996.
71. Pedrazzoli P., Farris A., Del Prete S., et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. JClin Oncol 2008, 26(10):1619-1625.
72. Henry D., Dahl N., Auerbach M., et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007, 12(2):231-242.
73. Hedenus M., Birgegård G., Näsman P., et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007, 21(4):627-632.
74. Steensma D., Sloan J., Dakhil S., et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. JClin Oncol 2011, 29(1):97-105.
75. Gafter Gvili A., Rozen Zvi B., Vidal L., et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials. Acta Oncol 2013, 52(1):18-29.
76. Muñoz M., Gómez-Ramírez S., Cuenca J., et al. Very-short-term perioperative intravenous iron administration and postoperative outcome in major orthopedic surgery: a pooled analysis of observational data from 2547 patients. Transfusion 2014, 54(2):289-299.
77. Brockow K., Garvey L.H., Aberer W., et al. Skin test concentrations for systemically administered drugs - an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013, 68(6):702-712.
78. Baur X., Bakehe P. Allergens causing occupational asthma: an evidence-based evaluation of the literature. Int Arch Occup Environ Health 2014, 87(4):339-363.
79. Makrilia N., Syrigou E., Kaklamanos I., et al. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs 2010, 2010. pii:207084.
80. Ebo D.G., Leysen J., Mayorga C., et al. The invitro diagnosis of drug allergy: status and perspectives. Allergy 2011, 66(10):1275-1286.
81. Leysen J., Sabato V., Verweij M., et al. The basophil activation test in the diagnosis of immediate drug hypersensitivity. Expert Rev Clin Immunol 2011, 7(3):349-355.
82. Ljungström K.G. Safety of dextran in relation to other colloids-ten years experience with hapten inhibition. Infusionsther Transfusionsmed 1993, 20(5):206-210.
83. Aberer W., Bircher A., Romano A., et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003, 58(9):854-863.
84. Cernadas J.R., Brockow K., Romano A., et al. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy 2010, 65(11):1357-1366.
85. Brockow K., Romano A., Aberer W., et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy 2009, 64(2):234-241.
86. de Barrio M., Fuentes V., Tornero P., et al. Anaphylaxis to oral iron salts. Desensitization protocol for tolerance induction. JInvestig Allergol Clin Immunol 2008, 18(4):305-308.